Study Details

Back to Search Results

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

This trial is recruiting
The study is currently recruiting participants.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT05014139

Astellas Study ID

The unique identification code given by the study sponsor.

SGN22E-004

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Bladder Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 Years - N/A

Sex

Female & Male

Product

enfortumab vedotin

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Dec 2021 - May 2028

Masking

None (Open Label)

Enrollment number

58

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients with Non-muscle Invasive Bladder Cancer (NMIBC)

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

MD Anderson

Houston, United States, 77030

Recruiting
Contact Us

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

New York, United States, 10016

Study Complete
Contact Us

Johns Hopkins Medical Center

Baltimore, United States, 21287

Recruiting
Contact Us

Duke University Medical Center

Durham, United States, 27710

Study Complete
Contact Us

University of California, Irvine

Orange, United States, 92868

Recruiting
Contact Us

Site ES34001

Barcelona, Spain, 08025

Recruiting
Contact Us

University of Texas Southwestern Medical Center

Dallas, United States, 75390

Recruiting
Contact Us

Site CA11001

Toronto, Canada, M5G 2C1

Recruiting
Contact Us

Site FR33001

Paris, France, 75013

Recruiting
Contact Us

University of California at San Francisco

San Francisco, United States, 94134

Recruiting
Contact Us

Site ES34003

Barcelona, Spain, 08036

Recruiting
Contact Us

Site ES34002

Madrid, Spain, 28041

Recruiting
Contact Us

Site UK44002

London, United Kingdom, EC1A 7BE

Recruiting
Contact Us

UCLA Department of Medicine - Hematology & Oncology

Los Angeles, United States, 90095

Recruiting
Contact Us

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo